307 related articles for article (PubMed ID: 17017974)
1. Targeting tumor-related immunosuppression for cancer immunotherapy.
Frumento G; Piazza T; Di Carlo E; Ferrini S
Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):233-7. PubMed ID: 17017974
[TBL] [Abstract][Full Text] [Related]
2. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
3. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells: a potential target in cancer immunotherapy.
Shitara K; Nishikawa H
Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil--CD4+CD25+ T regulatory cell interactions: a possible new mechanism of infectious tolerance.
Lewkowicz N; Klink M; Mycko MP; Lewkowicz P
Immunobiology; 2013 Apr; 218(4):455-64. PubMed ID: 22749980
[TBL] [Abstract][Full Text] [Related]
6. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
9. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
10. [The role of regulatory T cells in the modulation of anti-tumor immune response].
Radosavljević GD; Jovanović IP; Kanjevac TV; Arsenijević NN
Srp Arh Celok Lek; 2013; 141(3-4):262-7. PubMed ID: 23745355
[TBL] [Abstract][Full Text] [Related]
11. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
Munn DH; Mellor AL
Trends Immunol; 2016 Mar; 37(3):193-207. PubMed ID: 26839260
[TBL] [Abstract][Full Text] [Related]
12. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors.
Kabelitz D; Wesch D; Oberg HH
Crit Rev Immunol; 2006; 26(4):291-306. PubMed ID: 17073555
[TBL] [Abstract][Full Text] [Related]
13. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-beta.
Satoguina JS; Adjobimey T; Arndts K; Hoch J; Oldenburg J; Layland LE; Hoerauf A
Eur J Immunol; 2008 Nov; 38(11):3101-13. PubMed ID: 18924213
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
15. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells.
Wang B; Li B; Dai Z; Ren S; Bai M; Wang Z; Li Z; Lin S; Wang Z; Huang N; Yang P; Liu M; Min W; Ma H
Int J Biochem Cell Biol; 2014 Oct; 55():98-108. PubMed ID: 25168696
[TBL] [Abstract][Full Text] [Related]
16. The characterization and role of regulatory T cells in immune reactions.
Wilczynski JR; Radwan M; Kalinka J
Front Biosci; 2008 Jan; 13():2266-74. PubMed ID: 17981708
[TBL] [Abstract][Full Text] [Related]
17. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.
Tsaknaridis L; Spencer L; Culbertson N; Hicks K; LaTocha D; Chou YK; Whitham RH; Bakke A; Jones RE; Offner H; Bourdette DN; Vandenbark AA
J Neurosci Res; 2003 Oct; 74(2):296-308. PubMed ID: 14515359
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
19. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response.
Stoop JN; Woltman AM; Biesta PJ; Kusters JG; Kuipers EJ; Janssen HL; van der Molen RG
Hepatology; 2007 Sep; 46(3):699-705. PubMed ID: 17654744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
